Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis

Drug Design, Development and Therapy

Volumn 11, Issue , 2017, Pages 909-921

  Sato, Mariana R ^a   Oshiro Junior, João A ^a   Machado, Rachel T A ^a   de Souza, Paula C ^a   Campos, Débora L ^a   Pavan, Fernando R ^a   da Silva, Patricia B ^a   Chorilli, Marlus ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Copper(II) complex; In vitro activity; In vivo acute toxicity assay; M. tuberculosis; Nanostructured lipid carriers; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CUPRIC ION; NANOMATERIAL; COPPER; DRUG CARRIER; LIPID; ORGANOMETALLIC COMPOUND; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATOMIC FORCE MICROSCOPY; CARDIOTOXICITY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSITY; DNA SYNTHESIS; ENERGY METABOLISM; ENZYME ACTIVITY; EUROPEAN MEDICINES AGENCY; FEMALE; HYDRODYNAMICS; HYDROGENATION; LD50; LIVER TOXICITY; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL CHEMISTRY; RESPIRATORY FUNCTION; TUBERCULOSIS; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

ANIMALS; ANTITUBERCULAR AGENTS; COPPER; DRUG CARRIERS; FEMALE; LIPIDS; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NANOSTRUCTURES; ORGANOMETALLIC COMPOUNDS;

EID: 85016114001     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S127048     Document Type: Article

References (57)

1. Nogueira AF, Facchinetti V, Souza MV, Vasconcelos TR. Tuberculose: uma abordagem geral dos principais aspectos. [Tuberculosis: a general approach of the main aspects] Rev Bras Farm. 2012;93(1):3-9. Portuguese.
2. World Health Organization. Global Tuberculosis Report 2015. Geneva: World Health Organization Press; 2015. Available from: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf. Accessed February 3, 2017.
3. Jadhavar PS, Vaja MD, Dhameliya TM, Chakraborti AK. Oxazolidinones as anti-tubercular agents: discovery, development and future perspectives. Curr Med Chem. 2015;22(38):4379-4397.
4. Drobniewski F, Nikolayevsky V, Maxeiner H, et al. Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation. BMC Med. 2013;11:190.
5. Sharma AK, Kumar R, Nishal B, Das O. Nanocarriers as promising drug vehicles for the management of tuberculosis. BioNanoSci. 2013;3(2):102-111.
6. Bonnet M, Bastard M, Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis. 2015;20(2):177-186.
7. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC. Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J. 2015;45(4):1119-1131.
8. Sato MR, Silva PB, Souza RA, Santos KC, Chorilli M. Recent advances in nanoparticle carriers for coordination complexes. Curr Top Med Chem. 2015;15(4):287-297.
9. Medici S, Peana M, Nurchi VM, Lachowicz JI, Crisponi G, Zoroddu MA. Noble metals in medicine: latest advances. Coord Chem Rev. 2015;284:329-350.
10. Pavan FR, Poelhsitz GV, Barbosa MI, et al. Ruthenium(II) phosphine/diimine/picolinate complexes: inorganic compounds as agents against tuberculosis. Eur J Med Chem. 2011;46(10):5099-5107.
11. Rodrigues MA, Silva PP, Guerra W. Cobre. [Copper]. QNEsc. 2012;34:161-162.
12. Speer A, Shrestha TB, Bossmann SH, et al. Copper-boosting compounds: a novel concept for antimycobacterial drug discovery. Antimicrob Agents Chemother. 2013;57(2):1089-1091.
13. Salsbury LE, Robertson KN, Flewelling AJ, et al. Anti-mycobacterial activities of copper(II) complexes. Part II. Lipophilic hydroxypyridinones derived from maltol. Can J Chem. 2015;93(3):334-340.
14. Hoffman AE, DeStefano M, Shoen C, et al. Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis. Eur J Med Chem. 2013;70:589-593.
15. Silva PB, Bonifácio BV, Frem RC, et al. A nanostructured lipid system as a strategy to improve the in vitro antibacterial activity of copper(II) complexes. Molecules. 2015;20(12):22534-22545.
16. de Freitas ES, Silva PB, Chorilli M, et al. Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds. Molecules. 2014;19(5):5999-6008.
17. Silva PB, Souza PC, Calixto GM, et al. In vitro activity of copper(II) complexes, loaded or unloaded into a nanostructured lipid system, against Mycobacterium tuberculosis. Int J Mol Sci. 2016;17(5):745.
18. Bonifácio BV, Ramos MA, da Silva PB, et al. Nanostructured lipid system as a strategy to improve the anti-Candida albicans activity of Astronium sp. Int J Nanomedicine. 2015;10:5081-5092.
19. Radtke M, Muller RH. Nanostructured lipid drug carriers. New Drugs. 2001;48-52.
20. Yang Y, Corrona A 3rd, Schubert B, Reeder R, Henson MA. The effect of oil type on the aggregation stability of nanostructured lipid carrier. J Colloid Interface Sci. 2014;418:261-272.
21. Souto EB, Severino P, Santana MHA, Pinho SC. Nanopartículas de lipídicos sólidos: métodos clássicos de produção laboratorial. [Solid lipid nanoparticles: classical methods of lab production]. Quím Nova. 2011;34(10):1762-1769. Portuguese.
22. Muller RH, Radtke M, Wissing AS. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131-S155.
23. Muller RH, Radtke M, Wissing AS. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1-2):121-128.
24. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2002;46(8):2720-2722.
25. Lopes Ede O, Oliveira CG, Silva PB, et al. Novel zinc(II) complexes [Zn(atc-Et)2] and [Zn(atc-Ph)2]: in vitro and in vivo antiproliferative studies. Int J Mol Sci. 2016;17(5):E781.
26. Gruppo V, Johnson CM, Marietta KS, et al. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006;50(4):1245-1250.
27. Golde WT, Gollobin P, Rodriguez LL. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim (NY). 2005;34(9):39-43.
28. Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139-151.
29. Fonseca-Santos B, Gremião MP, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2015;10:4981-5003.
30. Hejri A, Khosravi A, Gharanjig K, Hejazi M. Optimisation of the formulation of β-carotene loaded nanostructured lipid carriers prepared by solvent diffusion method. Food Chem. 2013;141(1):117-123.
31. Schwarz C, Mehnert W, Lucks J, Müller R. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release. 1994;30(1):83-96.
32. Krause B, Mende M, Potschke P, Petzold G. Dispersability and particle size distribution of CNTs in an aqueous surfactant dispersion as a function of ultrasonic treatment time. Carbon. 2010;48:2746-2754.
33. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012;20(10):813-830.
34. Ali H, El-Sayed K, Sylvester PW, Nazzal S. Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: evidence studies by differential scanning calorimetry (DSC) and proton nuclear magnetic resonance spectroscopy ((1)H NMR). Colloids Surf B Biointerfaces. 2010;77(2):286-297.
35. Severino P, Pinho SC, Souto EB, Santana MH. Polymorphism, crystallinity and hydrophilic-lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles. Colloids Surf B Biointerfaces. 2011;86(1):125-130.
36. Tan SW, Billa N, Roberts CR, Burley JC. Surfactant effects on the physical characteristics of amphotericin B-containing nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp. 2010;372(1-3):73-79.
37. Obeidat WM, Schwabe K, Muller RH, Kech CM. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2010;76(1):56-67.
38. Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm. 2006;314(1):56-62.
39. zur Muhlen A, zur Muhlen E, Niehus H, Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res. 1996;13(9):1411-1416.
40. Lira A, Araújo A, Basílio I, Santos B, Santana D, Macedo R. Compatibility studies of lapachol with pharmaceutical excipients for the development of topical formulations. Thermochim Acta. 2007;457(1-2):1-6.
41. Cides LC, Araújo AA, Santos-Filho M, Matos J. Thermal behaviour, compatibility study and decomposition kinetics of glimepiride under isothermal and non-isothermal conditions. J Therm Anal Calorim. 2006;84(2):441-445.
42. Lavor EP, Freire FD, Aragão FS, Raffin FN, Moura TF. Application of thermal analysis to the study of anti-tuberculosis drug compatibility. Part 1. J Therm Anal Calorim. 2012;108(1):207-212.
43. Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 5th ed. London: Pharmaceutical Press; 2006.
44. Silva RC, Escobedo JP, Gioielli LA. Comportamento de cristalização de lipídios estruturados por interesterificação química de banha e óleo de soja. [Crystalization behavior of structured lipids by chemical interesterification of lard and soybean oil]. Quím Nova. 2008;31(2):330-335. Portuguese.
45. Rigon RB, Fachinetti N, Severino P, Santana MHA, Chorilli M. Skin delivery and in vitro biological evaluation of trans-resveratrol-loaded solid lipid nanoparticles for skin disorder therapies. Molecules. 2016;21(1):E116.
46. Bottom R. The role of modulated temperature differential scanning calorimetry in the characterization of molecule exhibiting polymorphic and glass forming tendencies. Int J Pharm. 1999;92(1):47-53.
47. Hunoor RS, Patil BR, Badiger DS, et al. Spectroscopic, magnetic and thermal studies of Co(II), Ni(II), Cu(II) and Zn(II) complexes of 3-acetylcoumarin-isonicotinoylhydrazone and their antimicrobial and anti-tubercular activity evaluation. Spectrochim Acta A Mol Biomol Spectrosc. 2010;77(4):838-844.
48. Mandewale MC, Thorat B, Shelke D, Yamgar R. Synthesis and biological evaluation of new hydrazone derivatives of quinoline and their Cu(II) and Zn(II) complexes against Mycobacterium tuberculosis. Bioinorg Chem Appl. 2015;2015:153015.
49. dos Santos ER, Mondeli MA, Pozzi LV, et al. New ruthenium(II)/phosphines/diimines complexes: promising antitumor (human breast cancer) and Mycobacterium tuberculosis fighting agents. Polyhedron. 2013;51:292-297.
50. Global Alliance for TB drug development. Handbook of anti-tuberculosis agents. Tuberculosis. 2008;88(2):85-170.
51. Ayla-Torre C, Hernández N, Galeano A, Novoa-Aponte L, Soto C. Zeta potential as a measure of the surface charge of mycobacterial cells. Ann Microbiol. 2014;64(3):1189-1195.
52. Stokes RW, Norris-Jones R, Brooks DE, Beveridge TJ, Doxsee D, Thorson LM. The Glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages. Infect Immun. 2004;72(10):5676-5686.
53. OECD.org [homepage on the Internet]. Guideline 423: Acute Oral Toxicity-Acute Toxic Class Method. Paris: Head of Publications Service; 2011. Available from: http://www.oecd.org/publications. Accessed March 23, 2016.
54. Liu X, Hamnvik PO, Chamberland JP, et al. Circulating alanine transaminase (ALT) and γ-glutamyltransferase (GGT), but not fetuin-A, is associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus metabolism study. Metabolism. 2014;63(6):773-782.
55. Sohn W, Jun DW, Kwak MJ, et al. Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea. J Gastroenterol Hepatol. 2013;28(3):522-529.
56. Amir N, Suprayitno E, Nursyam HH. The effect of cypermethrin on Jambal Roti to AST and ALT levels the Wistar rat (Rattusnorvegicus). Int J Pharm Tech Res. 2015;8(2):235-240.
57. Hyder MA, Hasan M, Mohieldein AH. Comparative levels of ALT, AST, ALP and GGT in liver associated diseases. Eur J Exp Biol. 2013;3(2):280-284.